You are on page 1of 9



Company Profile

Supervised by

Professor Pares Chandra Mondale

Department of
Masters of Business Studies
Jagannat University Bangladesh

Submitted by

Md. Golam Kibria

ID No: MBS 560068

Department of Business Studies

Jagannat University Bangladesh

Feb 20, 2010.

Professor Pares Chandra Mondale

Department of
Masters of Business Studies
Jagannat University of Bangladesh

Subject: Letter of Transmittal


I am presenting my internship report “Financial Management of

Pharmaceuticals Company: Study on Incepta Pharmaceuticals LTD
I have collected as much information as possible from pharmaceuticals
activities of the IPL. Three months works on this organization was a worthwhile
experience for me as it was in such a reputed organization. It is a great pleasure
for me to present you the report as a requirement of with the Masters of
Business Administration.

I believe that this internship program has enriched both my knowledge and

Sincerely Yours,

Md. Golam Kibria
ID No: MBS 560068
Department of Business Studies
Jagannat University Bangladesh


While preparing this report, I have been fortunate to have the support, assistance
and encouragement of a number of individuals. Many of them played a decisive
role in helping me writing this report.

I am very much grateful to my honorable advisor Professor Pares Chandra

Mondale for assigning me to prepare this report. He has guided me in
coordinating the whole report. He has taken time to check the report and has
given her suggestion on different portion of the report. Without his help, it
would have been difficult to prepare the report.

My heartiest thanks and gratitude to Md. Sultan Mahmood, Assistant manager,

Finance & Accounts, Incepta Pharmaceuticals Ltd. for giving me the
opportunity to fulfill my Internship program.

Special thanks go to Md. Zakir Khan (Assistant manager), Human Resources

Department, Mohammad Monwarul Islam (Sr. Executive Officer), Finance &
Accounts Department and Syed Md. Ashhaduzzaman (Sr. Executive Officer),
Finance & Accounts Department, Incepta Pharmaceuticals Ltd.

And finally, I convey my sincere thanks to all the individuals of Incepta

Pharmaceuticals Ltd. Who have helped me prepare this report successfully?

(Md. Golam Kibria)

ID No: MBS 560068

Major in Accounting

Department of

Masters of Business Studies (in Accounting)

Jagannat University Bangladesh

Company profile


Incepta Pharmaceuticals Ltd. is a leading pharmaceutical company in

Bangladesh. Established in the year 1999, the company’s commercial operation
started in 2000. The company has a very big manufacturing facility located at
Savar, 35 kilometer away from the center of the capital city Dhaka. The
company produces various types of dosage forms which include tablets,
capsules, oral liquids; injection ampoules, dry powder vials; powder for
suspension, cream/ointment, nasal sprays, eye drops, etc. Since its inception,
Incepta has been launching new and innovative products in order to fulfill
unmet demand of the medical community. The focus was to bring more new
technologically advanced molecules to this country.

The company specializes in value added high technology dosage forms like
sustained release tablets, quick mouth dissolving tablets, barrier coated delayed
release tablets etc. It has established a modern research and development
laboratory for the development of new advanced dosage forms for various drugs
and devices like poorly soluble drugs, dry powder inhalers, coated pellets,
modified release products, taste masked preparation etc.

Incepta has quickly developed a very competent sales team, which promotes the
specialties throughout the country. The company virtually covers every single
corner of the rural as well as urban area of Bangladesh. It has its own large
distribution network having 14 depots all over the country. The company has a
clear vision to become a leading research based dosage form manufacturing
company with global presence within a short period of time.

The Research and Development department for various dosage forms has been
very well developed. Incepta intends to bring newer products of advanced
technology through research hitherto unknown in this country. Such activities
will not only benefit the company but also the total pharmaceutical sector of the
country. The company also intends to embark into the production of Active
Pharmaceutical Ingredient (API). Plans are underway to get into reverse
engineering and analogue research in order to produce new API.

The company is now expanding its activities beyond the geographical boundary
of Bangladesh. The products are of high standard and therefore these will be
exported to both developed and developing countries. The company is open to
collaborate with interested parties in various countries. The future is wide open
and the opportunities are bountiful. Incepta will continue to strive to provide
high quality medicine at affordable prices to the people here in Bangladesh and
other parts of the globe.

2. Name of Company : Incepta Pharmaceuticals Limited

• Address Head Office:

: 40, Shahid Tajuddin Ahmed Sharani,
Tejgaon Industrial Area, Dhaka-1208,
: Bara Rangamatia, Zirabo, Savar, Dhaka

• Telephone : +880-2-883 7811-26,


• Fax : +880-2-8837952

• E-mail :

• Website :

3. Year of Establishment : 1999

4. Form of Company : Private Limited

5. Total number of employees : 3050

Scientific & Technical : 191
Others : 2859

6. Capital
Value of Authorized capital : 16.00 million USD
Paid up capital/ Reserves : 7.50 million USD/ 4.16 million USD

7. Total Sales turnover in the previous four years-each year separately

(split between Export and domestic) sale:

Year 2009 2008 2007 2006 2005 2004

Export Sale (Thousand 3350
3020 2428 450 - -
Domestic Sale (Million 52.14
48.32 41.14 36.76 30 23.7

8. Growth Rate (as %):

Year 200 2008 2007 2006 2005 2004

Turnover 50.387 27.36 17.10 24.80 26.58 46.29

9. Manufacturing facilities:

Strength and capability of Incepta Pharmaceuticals Limited is now well

established with strong quality image in Bangladesh pharmaceutical market. It
has its own manufacturing plant which is WHO-GMP compliant and certified
with approval from international organizations. Recently the facility has got
European “Certificate of GMP Compliance”.
The pharmaceutical plant is located at Zirabo, Savar about 35 kilometers from
the capital city and is spread over the land of about 151,000 square feet area
(approx.14,000 square meter) with a build-up total floor area of about 231,400
square feet (approx.21,500 square meters) with state of the art manufacturing
facilities. The plant manufactures tablets, capsules, oral liquids and Injectables,
nasal sprays, creams, ointments, ophthalmic products, sachets, powder for oral
suspensions, spray dried specialized dosage forms etc.
Cephalosporin group of products are manufactured in a completely separate

Address of Factory: Dewan Idris Road, Bara Rangamatia, Zirabo, Savar, Dhaka.
Telephone : +880-2-7708502 - 6, Fax: +880-2-7708507

Total Floor Area of the Factory:

General Production Area – Approx. 27,000 ft2 (2,509 m2) *

Hi-Tech Production Area – Approx. 9,150 ft2 (850 m2) *
Cephalosporin Production Area – Approx. 15,500 ft2 (1,440 m2) *
Lyo Production Area – Approx. 18,120 ft2 (1,684 m2) *
Lyo Other Area – Approx. 18,120 ft2 (1,684 m2)
Liquid (New) Production Area – Approx. 21,320 ft2 (1,981 m2) *
Warehouse – Approx. 41,000 ft2 (3,810 m2)
QA/QC – Approx. 11,500 ft2 (1,068) m2 *
Administration – Approx. 8,830 ft2 (821 m2) *
R&D Formulation – Approx. 9,080 ft2 (844 m2) *
Canteen, Laundry & others – Approx. 22,700 ft2 (2,110 m2)
Utility & others – Approx. 17,034 ft2 (1583 m2)
Engineering – Approx. 12,000 ft2 (1,115 m2)

* Equal amount of service floor area is available which is not shown here.

The installed production capacities are –


Tablets : 1920.00 Million/Year

Capsules : 120.00 Million/Year
Liquid Injection ampoules : 24.96 Million /Year
Eye Drops : 3.00 Million/Year
Infusion Bags : 1.92 Million Bags/Year
Infusion Bottles : 0.80 Million Bottles/Year
Liquid Injection Vials : 0.60 Million/Year
Dry Vial for Injection : 2.70 Million/Year
Nasal Spray : 2.57 Million Vials/Year
Cream/Ointment./Shampoo : 5.26 Million Tubes/Year
Oral Liquids : 29.48 Million Bottles/Year
Powder for Oral Suspensions : 3.80 Million Bottles /Year
Sachet of Oral Powder : 19.80 Million Sachets/Year
Lyophilized vials : 1.80 Million /Year
Pre-filled Syringes : 1.80 Million /Year


Tablets : 90.00 Million/Year

Capsules : 76.00 Million/Year
Powder for Oral Suspensions : 3.24 Million Bottles /Year
Dry Vial for Injection : 6.00 Million/Year

The plant employs about 700 people and has manufacturing and warehousing
facilities, quality control and quality assurance, R&D Formulation, engineering

10. Export:

Existing Country: Afghanistan, Belize, Bhutan, Congo, Costa Rica, Cambodia,

Dominican Republic, El Salvador, Ethiopia, Guyana, Georgia, Hong Kong,
Honduras, Kenya, Myanmar, Mongolia, Mauritania, Sri Lanka, Somalia, Togo,
Tajikistan, Turkey, Ukraine, Vietnam.

Pipeline country : Armenia, Austria, Azerbaijan, Burundi, Burkina Faso,

Benin, Chile, Egypt, Ghana, Germany, Ivory Coast, Indonesia, Iran, Jordan,
Kuwait, Philippines, Saudi Arabia, Libya, Laos, Macau, Malaysia, Maldives,
Moldova, Mali, Mozambique, Niger, Pakistan, Panama, Russia, Thailand,
Tanzania, Sudan, South Africa, Sierra Leon, Yemen, Uganda and UAE.
Future Plan: Algeria , Angola, Argentina, Brazil, Bolivia, Belarus, Canada,
Gabon, Kazakhstan, Mexico, Morocco, Peru, Qatar, Singapore, Senegal, Syria,
Trinidad & Tobago, Turkmenistan, USA, Zimbabwe

11. Position in Industry:

According to IMS health survey, our position in the industry is currently 2nd in
2010 with the highest growth rate among the top 10 companies here in